



GLUBRAN®2 for endovascular use: indications and techniques

Prof. Romaric LOFFROY

*Department of Vascular & Interventional Radiology,
CHU Dijon Bourgogne*

HOW TO BECOME GLUE CONFIDENT





Index

3	Presentation
5	Introduction
5	Embolic agents
7	Why Glubran® 2
15	General instructions
15	Coaxial technique
15	Glubran® 2 + Ethiodized Oil: how to prepare the mixture
17	Embolization technique
21	Example
23	Polymerization
26	Dilution ratios per indication
28	Clinical applications
28	Arterial approach
28	Buttock AVM
31	Uterine AVM
34	Cardiac hyperflow related dyspnea
38	Endoleak type II
41	False aneurysm
41	Angiomyolipoma
44	Kidney pseudoaneurysm
44	Humeral bone metastasis
45	Tibial bone metastasis
51	Gastrointestinal bleeding
53	How to avoid ischemic complications
55	Extravasation control
61	Prostatic embolization
64	Varicocele
67	Pelvic Congestion Syndrome (PCS)
68	False aneurysm at the common femoral artery
70	Conclusions
71	Take home messages
72	References

GLUBRAN[®] 2

for endovascular use: indications and techniques

Editorial coordination:

Ferdinando Maggio & Massimiliano Mattioli

Graphic project:

Massimo Di Leo

All rights reserved.

© Copyright 2022

medimay
COMMUNICATION

www.medimay.it

Please scan the
QR Code to watch
the video



SCAN ME

Presentation

Most interventional radiologists see the use of glue as a practice that can lead to multiple complications, chiefly the risk of the catheter sticking to the vessel and generating non-target embolization. During this training, some useful advice will be offered towards performing a safe and proper embolization, helping the radiologist to avoid such risks.

This booklet wants to be an accessory of this hands-on course on the use of the glue Glubran®2 as liquid embolizing agent. It has been created with the dual purpose of supporting the trainee during the theoretical part of the training and of releasing basic information, instructions, tips and tricks the Radiologist can consult before starting the first experiences of embolization with “glue” independently.

Prof. Romaric Loffroy

GLUBRAN[®]2
ENDOVASCULAR

SOLVES.

**Building
the perfect
Embolization**



GEM SOLUTION
COMES FROM
EVOLUTION.

Introduction

Embolic agents

Embolic agents can be classified into solids, particles and liquids. Solid agents that can be positioned at target site include coils and microcoils, plugs, and balloons. Agents to be released in the bloodstream can be sub-categorized into *particles* and *liquids*: particles can be absorbable or non-absorbable, spherical or non-spherical; liquid agents include cyanoacrylates, gelling solutions, and sclerosing agents (Fig.1). While indications such as varicocele respond well to any kind of treatment, others, such as lower gastrointestinal (GI) bleeding, offer a restricted choice, as the radiologist may have to reach a very distal vessel by using means of a small microcatheter.




Figure 1

In such cases, liquids are often the best solution, as it may be difficult to properly deploy solid agents, even when it comes to small microcoils (Fig.2). On the contrary, injecting liquid is a viable option in any kind of indication. An interventional radiologist needs to be able to master every tool at their disposal. Gelling solutions or coils can prove efficacious in many cases, however, some indications require a combination of liquid and solid agents or, as this presentation will show, sometimes glue simply represents the best option. The oldest cyanoacrylate for endovascular use is Butyl (NBCA), known as Histoacryl[®] in Europe and Asia, and Truefill[®] in the United States. Although Histoacryl[®] is normally employed in endovascular use, it is never commercially promoted as a product suitable for this kind of environment as it lacks official approval. Truefill[®] has FDA approval, however, it is only available in the US. The lack of a CE marking is not the only downside to employing Histoacryl[®]. As one of the most common causes for complications is dried glue causing the microcatheter to stick to the vessel, quick polymerization may increase such risk (Fig.3).




Figure 2

Why Glubran® 2

At this moment in time Glubran® 2 (NBCA + Methacryloxy Sulfolane) is the only certified glue for endovascular use in Europe (Fig.4).

The co-monomer allows for better stability and for a spontaneously delayed polymerization time, which makes it less challenging to deploy when compared to Histoacryl® (Fig.5). Another liquid agent is MagicGlue® from Balt, formerly known as Purefill® (Fig.6).

Comparing polymerization time, levels of cytotoxicity and inflammation, and adhesive strength across all available products, Glubran® 2 appears to be a perfectly balanced agent in terms of behaviour. It therefore represents a favourable option in many indications.

As costs usually represent a relevant factor, **a great advantage to favoring Glubran® 2 is its price.** The price of Ethiodized Oil (Lipiodol®) has been rising consistently over the past 5 years: today, it is about € 250.00 for 10 ml. Since Trufill® comes packaged together with Ethiodized Oil, this may be one of the

Cyanoacrylates: types and actions

	Methyl (NMCA)	Butyl (NBCA)		Hexyl (NECA)
	Superglue®	NBCA Histoacryl® Trufill®	NBCA + CM Glubran® 2	MagicGlue®
CH3 radical	+	++	++	+++
Polymerization time	Very fast	Fast	Intermediate	Low
Cytotoxicity	+++	++	+	+
Inflammation	+++	++	+	+
Adhesive strength	+++	+++	++	+



Used for endovascular purpose

Figure 3

GLUBRAN®2

for endovascular use: indications and techniques


reasons for its excessive cost. A 1 ml vial is about \$ 3,000.00, whereas the same amount of Glubran®2 costs about € 100.00. The cost of the mixture may be compared to purchasing a single plug or one detachable microcoil. Onyx® or Squid are about twice the price. Usually, fixing an artery requires 3 to 6 microcoils, whereas a single drop of glue will produce the same results (Table 1). Another upside is that **Glubran®2 comes in vials of variable capacity (0.25/0.5/1 ml)**. This makes it **quite practical as we do not always need the same amount of product**. While veins require the entire space to be filled,

Product	Average price
Glubran® 2 (1 ml) + Lipiodol® (10 ml)	350.00 €
3-4 detachable microcoils	1,050.00-1,400.00 €
Microparticles (1 vial)	300.00 €
Onyx® (1 vial)	650.00 €


Table 1 - Cost consideration.

Glubran®2


- GEM Srl, Viareggio, Italy
- Allowed for endovascular purpose
- Except in the US and Japan
- CE marking
- Very cheap +++ ≈ 100€

CCCC#N

NBCA

CC(C)=CC(=O)OC

MS






Figure 4

Glubran® 2 vs Histoacryl®

Advantages of cyanoacrylate monomer over classic cyanoacrylate

Glubran®2

- Polymerizes at 45° C
- Polymerizes in 30-90 sec
- Flexible
- CE mark

Histoacryl®

- Polymerizes at 90° C
- Polymerizes instantaneously
- Friable, stiff, breakable
- No CE mark

Figure 5

MagicGlue® vs Glubran® 2...


- Less transparent (more yellow)
- More stable after shaking
- Slower polymerization
- Longer time injection
- Less adhesive strength to the microcatheter
- More viscous
- A little bit more difficult to inject
(at same dilution & with same kind of syringe)

Figure 6

arteries can be occluded by using only a few drops. MagicGlue® from Balt is a “Me too” product in terms of CE marking. This means that no preclinical studies have been made, in fact, the studies from Glubran®2 have been used. The price of this product compares to that of Glubran®2. Glue is used in many fields, not only in interventional radiology but also in surgery. In Europe, it is widely employed in surgical environments, except for France, where the ratio is about 70-30% to interventional radiology. I estimate it is about the opposite in the rest of Europe. MagicGlue® often uses different names depending on the field: in surgery, it is often known as IFABOND, which sounds quite different. Glubran®2, on the other hand, is marketed under the same name in every field. Glubran®2 is transparent, colorless, highly adhesive, and hemostatic (Fig.7). The fact that the mixture with Ethiodized Oil dissolves polycarbonates might not be of specific interest to interventional radiologists, as we prefer to use different materials, but it is still worth mentioning. Not only it is an embolic agent, but it is a sclerosant, too, so it can be employed in a

Glubran® 2 features

- Transparent	- Radiolucent
- Colorless	- Typical smell
- Density similar to water	- Stable in air
- Highly adhesive	- Sclerosant
- Hemostatic	- Bacteriostatic
- Dissolving polycarbonates	- Cold storage



**Polymerizes on contact with
any fluid rich in OH – ions**

(blood, saline, some contrasts...)

Do not flush the catheter with saline or ionic contrast

Figure 7

variety of indications. It polymerizes in contact with any ion-rich fluid; therefore, it needs to be flushed with a 5% dextrose solution to prevent the blood from refluxing and polymerization from starting inside the catheter. In case of distal embolization such as a tumor, you need to abundantly flush the tumor bed, too, in order to make sure distal embolization is achieved. Polymerization of NBCA involves an exothermic reaction that is known to cause pain, even though this mechanism is not clinically obvious. Glubran®2 polymerizes at half the temperature as Histoacryl®, so it causes the patient less pain. Other differences include delayed polymerization, higher flexibility, and official approval. As previously mentioned, the advantages to using Glubran®2 are not limited to cost (Fig.8).

- **A quick embolization also implies less radiations, both for the surgeon and the patient.**
- **This product can be used in a number of indications, with bleeding as perhaps the most suitable.**

Advantages

- Inexpensive
- Quick → Less radiation
 - High flow AVM, type 2 endoleak
 - Trauma, bleeding
 - Tumors, false aneurysm, portal vein embolization
 - Gonadal veins: pelvic congestion, varicocele
- Permanent
- Efficacy does not depend on coagulation parameters
- Can reach distal targets that can not be navigated with catheters
 - Especially useful in bleeding conditions

Figure 8

- It is a permanent agent, exceptional when it comes to recanalization. This is not the case with all embolic agents.
- The fact that polymerization does not depend on coagulation parameters makes it very interesting in case of bleeding in patients with a coagulation disorder or low levels of platelets.

When Glubran® 2 comes into contact with blood, it **never fails to achieve occlusion**. Compared to mechanical agents, this poses a great advantage. In the use of coils, for example, a spontaneous thrombosis needs to be triggered and that can be challenging in patients with coagulation disorders.

- Distal targets are easily accessible even with the smallest microcatheter. In some specific indications, liquids are simply the best option.

When compared to Onyx®, Glubran® 2 is more thrombogenic and quicker to polymerize (Fig.9)⁽¹⁾. Inflammation rate is also higher. Even though Onyx® may be perceived as safer, as it ensures a more controlled release, in our experience this is not key in any indication. Besides, our concern here is peripheral

Glubran®2 vs Onyx®

Glubran®2

- Non-controlled release
- Quick polymerization
- Sticks to catheter
- Very sclerosant and adhesive
- No FDA approval
- Cheap

Onyx®

- Controlled release
- Slow polymerization
- Does not stick to catheter
- Cohesive no adhesive
- FDA approved
- Very expensive

Loffroy et al. Curr. Vascular. Pharmacol. 2009; 7;250-63

Figure 9

and visceral application, which is quite different from the neurological area. As previously mentioned, **Glubran®2 has high adhesive properties, but it still takes a long time for it to stick to the catheter. We have never experienced such an incident.** Onyx®, on the other hand, sometimes needs long breaks between injections, as it often causes immediate reflux. Neuro-radiologists may have to wait as long as 45 minutes between injections for a hard cast along the microcatheter to form so that they can push it again into the distal spot. The risk of finding the catheter stuck is quite high in such cases, and this is why there are specific microcatheters with detachable tips, so that the tip can be left in the patient and avoid an undesirable outcome. Most interventional radiologists see the use of glue as a practice that can lead to multiple complications, chiefly the risk of the catheter sticking to the vessel. During the course of this presentation, some useful advice will be offered towards performing a safe and proper embolization, helping the radiologist to avoid such risk entirely. Generally speaking, **while it may be possible to find the catheter hard to remove, the likelihood of it getting stuck to the point of not being able to remove is non-existent.** Ischemic risk is also a concern, as many perceive glue as a potentially dangerous agent with high risk of ischemic complications and necrotic lesions. In the past four years, two articles have been published regarding the use of glue in GI bleeding ^(2,3), showing how cyanoacrylate glue is the most clinically useful embolic agent in treating patients with acute NUGIB (non-variceal gastrointestinal bleeding), despite the need for a learning curve, especially in cases of coagulopathy. Despite the bowel being considered as the territory with the highest risk of ischemic complication, we showed that the risk rate is actually lower than with other embolic agents. Microparticles, for example, start from 14 microns in size and, when injected, the risk of ischemic complications is very high. Regardless of the level of dilution, combining Glubran® 2 with Ethiodized Oil makes the mixture highly viscous, which prevents it from reaching the capillaries. A viscous mixture will never become as distal as small microparticles. Non-target embolization caused by reflux

is indeed a possibility. Nonetheless, compared to other agents, the upside to employing glue is that it is clearly visible during the procedure. Particles, for instance, are only visible by means of the contrast agent that is added to them. Although due caution is certainly essential, the endpoint is that cyanoacrylates are easier to handle as they are easier to see.

Besides, as our area of interest is peripheral application, most times a few drops of glue in a non-target vessel will bear no consequences at all, so we can conclude that this kind of complication is not to be considered as such, but rather something we need to be aware of (Fig.10).

Drawbacks?

- Learning curve
 - Dilution
 - Optimal injection
 - Prevention of complications
 - + Sticking catheter?
 - > Never!
 - + Ischemic risk?
 - > Viscous!
 - + Non-target occlusion?
 - > No consequence!



Figure 10

General instructions

Coaxial technique

Using a **coaxial technique** guarantees **better maneuverability** and **additional protection**. **Inserting a microcatheter inside a standard 4 to 5 French catheter is a way to ensure safe and precise movements throughout the entire procedure.** Proceed then with flushing with 5% dextrose solution. Depending on the procedure, the microcatheter will have to be disposed of after use, as it may become too adherent. In case of portal vein embolization or varicocele, for example, the catheter may be used again as long as the next catheterism is not too complex. Going back in a second time will not be necessary after a proper embolization, as only a few drops of glue will ensure a perfect result.

Glubran® 2 + Ethiodized Oil: how to prepare the mixture

Glubran® 2 needs to be combined with Ethiodized Oil not only in order to make it radiopaque but also to be able to modulate the rate of polymerization. Depending on how distal the target is, a different ratio between the products will be needed (Figs.11,12).

In our practice, a 5 ml Luer-Lock syringe and a plastic 3-way stopcock are the standard instruments we use to dilute the glue. Avoid using polycarbonate tools as Ethiodized Oil dissolves this kind of material. A Luer-Lock system not only allows for a firm placement of the syringe but also for easier removal, as the syringe itself can be used to extract the catheter. Glubran®2 and Ethiodized Oil can be mixed by using two separate syringes. In order to make the mixture homogeneous, it is important to proceed slowly, in four or five steps, to avoid polymerization. You can detect such an instance by noticing the mixture turning white. According to dilution, a different gauge may be needed.

Instructions for use ⁽¹⁾

- **Using catheter/microcatheter:**

- Use the same setup everytime
- Standard 4 or 5F catheter
- Microcatheter is mandatory
- Previous catheter flushing with Glucose or 5% Dextrose
- Catheter becomes useless after embolization



Figure 11

Instructions for use ⁽²⁾

- **Mixing with Ethiodized Oil:**

- Makes the mixture radiopaque
- Modulates the rate of polymerization
- Plastic 3-way stopcock
- No polycarbonate luer-locked syringes



Figure 12

In our experience, a 2.8 Progreat® catheter and a 5 ml syringe offer a good balance between fluidity and resistance. When using a smaller microcatheter such as a 2.0, for instance, the mixture may be quite difficult to inject. In this case, the content of the syringe can be transferred into a smaller one, such as a 3 ml. Using 1 ml syringes is not advisable in our opinion, as the injection may feel too easy and lack the proper resistance.

Embolization technique

Ensure perfect stability of the catheter and perform a detailed angiography prior to the procedure. In order to calculate the volume, concentration, and velocity of the final glue injection, we need to perform several tests using a contrast agent (Fig.13). It is important to understand that the fluidity of these two liquids is not the same, as contrast is quite less viscous. Remember to take this factor into account when you estimate the distribution that the liquid will achieve upon injection.

Preparation

- **Preparation before injection:**
 - Stable catheter in target vessel
 - Very detailed previous angiography:
 - + Collaterals and non-target vessels
 - Calculate approximately the volume, concentration and velocity of the final glue injection:
 - + By doing previous several manual contrast injections



Figure 13

For the same reason, it is strongly advisable to pay attention to the strength we apply to the injections: always make sure you try to perform them in a similar way, so that the distribution of the liquid will be similar when you move on to injecting the mixture.

Figure 13 shows an example of considerable bleeding from the left gastric artery. The patient is hemodynamically stable and the branch can be sacrificed without consequences because of the collaterals. This is a typical embolization and we have a variety of choices to treat such a case. We can use gel foam or coils for example, however, we consider such choices as time consuming, as you may have to use a lot of coils and still not achieve complete occlusion. In this case, two drops of glue will bear great results, quickly, efficiently, and without risk. Conclusively, every time you can sacrifice the bleeding branch, which is most cases, this is undoubtedly the best course of action. Naturally, things would be different with the hypogastric artery or a pelvic trauma, for example. Provided that we always need to perform a slow and regular injection under strict fluoroscopic guidance, we can use different techniques to achieve proper embolization of our vessel (Figs. 14,15). Firstly, it is worth pointing out that the presence of blood flow does not prevent us from employing glue in our procedure. In fact, it is the opposite. A blood flow means that we can avoid reflux and safely push in the distal spot, as this presentation will show through practical examples. In most cases, though, we will perform a free flow injection.

- 1) Take a 5 ml syringe of dextrose solution and flush the dead space first, then
- 2) take another 5 ml syringe filled with the Glubran® 2 - Ethiodized Oil mixture and
- 3) start injecting slowly and continuously. Looking at the tip of the microcatheter, you will eventually see the mixture going distally, followed by a moment of stasis.
- 4) Your endpoint will be marked by some reflux happening at the tip or of the microcatheter or even a little before that point, and that is when you can stop injecting and
- 5) proceed to remove the microcatheter with your right hand by the 5 ml syringe itself. The presence of glue in the dead space is of no concern and,

in case of arteries, the 5 F catheter will be patent, which allows for better control through the catheter.

This is not the case with venous embolization when we are in presence of retrograde flow. For varicocele or pelvic congestion syndrome (PCS), when we remove the microcatheter we will likely occlude the 5 F catheter. This is not a problem but something we need to be aware of, since in that case we need to make sure not to push again, as we would be pushing something that is already polymerized and run the risk of migration. Keep in mind that this is indeed a false problem, as pushing again is impossible except with very small syringes. Provided that we perform the injection correctly and remember the difference in behavior between arteries and veins, this one-shot technique is ideal in many situations. Our second option is a multi-shot technique. After flushing the dead space with dextrose solution, we take only a small amount of mixture. As the dead space of a 2.7 microcatheter is about 0.6/0.7, a 0.2 ml is enough. We proceed with slowly injecting glue and dextrose solution in lay-

Embolization technique

- Slow and regular injection under strict fluoroscopic control:
- 3 techniques:
 - + Free-flow injection of boluses of a mixture of glue and ultrafluid Ethiodized Oil +++
 - "One-shot"
 - "Multi-shot"
 - + Blocked-flow injection to create vascular-tree casts under pressure
- No rush with catheter withdrawn
- Pull out curtly the catheter after getting your goal

Figure 14

ers, repeating the procedure as many times as needed. This will ensure that the dead space stays patent during the whole procedure. The drawback to this technique is not only that it is time-consuming, but also that the layers will rarely look neatly separated. We can never be sure whether the product at the end of the tip is glue or dextrose, and that is why I personally do not prefer this method, especially considering that maintaining the patency of the microcatheter is, in most cases, not mandatory. Carefully remove the microcatheter, not because it will stick as this is not a real risk, but in case any glue is left on the tip. If so, removing the catheter too quickly may break the glue and cause it to migrate to the distal spot, especially in case of arterial embolization.




Figure 15

Example

Figure 15 shows a free flow injection performed on a large hypervascular renal tumor. It is not rare to perform an embolization before a total nephrectomy, as this prevents bleeding or transfusions which would complicate the procedure. Reflux does not represent an issue in this case as the kidney can be sacrificed entirely, which makes this an easy embolization for the interventional radiologist. Start by placing a 5 F catheter at the proximal spot and the tip of the microcatheter in the trunk, about 1 cm away. Inject a high diluted mixture, using a 1:5 or 1:6 ratio. Observe the drops going distally and all the branches being reached by the reflux. Wait for stasis and more reflux. When the endpoint is reached, stop injecting and proceed with removing the microcatheter. There are many advantages to using glue. Indeed, this procedure may also be performed using microparticles, however, an additional mechanical agent should be placed at the main trunk, as microparticles alone would not be enough to occlude such a large area. Combining microparticles with coils or plugs means having to deploy two embolic agents, while glues will ensure you can perform both the distal and the proximal embolization by means of one agent only. Looking at the distribution of the liquid, we can observe that only the ostium is left patent for subsequent ligation, while every other part has been homogeneously reached by the glue. The endpoint is much more clearly visible as compared to a procedure performed using microparticles. Time is also a factor to be taken in consideration. Choosing the right size for the microparticles is an empirical process that requires some time. This method is overall rather time-consuming, as it needs to go through many different stages. First, we have to inject the microparticles very slowly, to ensure proper dilution. Then, we have to decide on the right size. We start the injection and wait for stasis, assess patency, add more particles if needed, taking

breaks between injections to allow for the reflux to stop. Glue, on the other hand, is clear, fast, and efficient. A procedure such as this will only take seconds to perform. Particles are perfectly suitable for some indications; however, it is not the same philosophy in terms of injections.

This is a typical free flow injection that is perfectly suitable for training. One thing to keep in mind is that when we embolize such large vessels, we may notice the bolus of glue growing bigger. In this case, do not fear it will not detach. Keep pushing and apply pressure to make sure it detaches and goes distally. As long as we do not have reflux, we can safely keep injecting the mixture. Once the glue has gone distally, wait for reflux and safely remove the microcatheter. You do not need to wait before doing so.

Figure 15 shows a pseudoaneurysm in the main trunk of the superior mesenteric artery. Most people would probably use a covered stent in this case; however, glue is a favorable alternative that will save the patient from having to take antiplatelet medications or risking long-term in-stent restenosis (ISR). We can use a very low dilution such as 1:0.5, just to make the mixture radiopaque while ensuring fast polymerization. Place the tip of the microcatheter at the back of the false aneurysm and inject very slowly to form a cast. The aneurysm will be filled and nothing will be left in the main trunk. Make sure you refrain from removing the microcatheter too soon and wait about 5 minutes for the polymerization to complete. Retracting the catheter too soon may result in the cast of glue being pulled back and migrating to the main trunk. There is no risk for a hydrophilic microcatheter to stick, especially considering we have the 5 F as a support.

Polymerization

Polymerization starts one or two seconds after the mixture comes into contact with blood, however, depending on the patient, we have one or more minutes before it ends. In case of distal embolization, after flushing the dead space we also abundantly flush the vascular bed to regulate the speed of the polymerization process (Fig.16). In a prostatic artery embolization, for example, we flush the gland and the distal bed with 5 or 10 ml of dextrose solution to leave the glue enough time to go distally. The ratio of our dilution also affects polymerization time. A more diluted mixture will take longer to complete the process (Figs. 17,18).

In most cases we use a 1:3 ratio. Almost any ratio will work with arteries.


Glue polymerization

- Polymerization period:
 - It starts 1-2 seconds after contact with blood
 - the end depends on the ratio (G2: Ethiodized Oil) i.e: from a minimum of 45 sec (1:1) up to 120 sec (1:6)
- We can regulate the speed of polymerization depending on:
 - Ethiodized Oil/glue ratio
 - Volume and lasting of the previous flushing with a non-ionic fluid the catheter and vascular bed
- We can allow the glue once released into the bloodstream about sailing away into distal beds or stay close for achieve a proximal occlusion

Figure 16

Polymerization time

NBCA-Ethiodized Oil mixture
dropped on plasma



1:1 mixture
(50% NBCA)

1:4 mixture
(20% NBCA)




Figure 17

Choosing glue dilution

NBCA-Ethiodized Oil ratio

	Low dilution (1:1 – 1:3)	High dilution (1:4 – 1:9)
Catheter position	Close to lesion	Away from lesion
Catheter tip	Wedged	Free
Injection manner	Continuous column	Drop by drop
Flow speed	Fast	Slow
Occlusion	Segmental	Peripheral
Application	Shunt	Organ, end artery

Figure 18

For veins, a pelvic congestion syndrome (PCS) or a varicocele, use a 1:1 low dilution. In case of reflux, we need to avoid migration at renal vein level. When we use a highly diluted mixture, we cannot intervene on the reflux as we first need to wait for the polymerization to complete. With a 1:1 ratio, polymerization starts immediately and there is no time for the glue to migrate, even in case of reflux. In case of distal embolization, for example with tumors, use a high dilution of 1:5 1:6. Also, when the tip of the microcatheter is far from the bleeding site and you need to reach the distal spot, use a higher dilution.

Dilution ratios per indication

What follows is a short list of indications with the respective dilution ratio. In clinical practice (Fig.19):

- 1:1 for varicocele
- 1:3 for 80-90% of cases
 - Peripheral bleeding
 - Pseudoaneurysms
 - GI bleeding
- 1:5 for peripheral AVMs
- 1:8 for portal vein embolization & PAE

The highest dilution is used in case of low flow, such as in procedures involv-

In clinical practice

- 1:1 for varicocele
- 1:3 for 80-90% of cases
 - Peripheral bleeding
 - Pseudoaneurysms
 - GI bleeding
- 1:5 for peripheral AVMs
- 1:8 for portal vein embolization & PAE

Figure 19

ing the portal vein system. A high dilution such a 1:8 ensures you can achieve a distal embolization.

At this moment in time, it appears that a plateau is reached at a ratio of 1:8 - 1:10. Beyond this point, while there would be no noticeable improvement in performance, the risk is that an excessively diluted mixture would result in poor adherence to the wall and the vessels, and may cause migration of the glue at a later time, when the patient is standing.

Now, we are going to show some examples of indications where glues have proved to be powerful allies.

Clinical applications

Arterial approach

The following are the clinical applications of the Glubran®2-Ethiodized Oil mixture ⁽⁴⁾ (Fig.20):

- Arteriovenous malformations (AVM)
- Acute arterial & venous bleeding
- Hypervascular tumors (primitive/metastasis)
- Portal vein embolization
- Endoleaks
- Varicocele / pelvic congestion syndrome
- Hypersplenism
- Prostatic artery embolization (PAE)
- Non-vascular purpose:
 - Needle track embolization
 - Enterocutaneous leaks
 - Biliary tract

Buttock AVM

In this first example we have a painful buttock AVM. The MR image shows it is very superficial (Fig.20AF). We first attempted an arterial approach and soon realized it was impossible to reach the nidus that way. We proceeded then by puncturing the nidus by the means of a 21 G Chiba needle and injected a 1:4 mixture of Glubran®2 and Ethiodized Oil. In a case such as this, extra caution is required to avoid venous drainage, however, when you first inject contrast to assess the flow, remember this liquid is rather less viscous than a 1:4 mixture of glue, and that makes it more likely to reach collaterals. Inject the glue slowly but do not worry about reaching as far as the contrast.

Clinical applications

- AVM
- Acute arterial & venous bleeding
- Hypervascular tumors (primitive/metastasis)
- Portal vein embolization
- Endoleaks
- Varicocele / pelvic congestion syndrome
- Hypersplenism
- PAE
- Non-vascular purpose:
 - Needle track embolization
 - Enterocutaneous leaks
 - Biliary tract




Figure 20




Figure 21 AB - 61 yo female - Painful buttock AVM - Nidus approach




Figure 21 CD






Figure 21 EF

In case of venous drainage in arms or legs, you can apply compression to stop the process. Keep injecting until you completely fill the nidus and reach your endpoint. Even though Onyx® might seem a good choice here, in case of very superficial AVMs it can be overly painful for the patient and sometimes leave marks on the skin. Glue is an easy and safe alternative.

Uterine AVM

A bleeding uterine AVM post-abortion with pseudoaneurysm and venous drainage (Fig.22AI). Using microparticles in this case would pose a serious risk of migration, whereas employing gel foam might result in an incomplete embolization. Notice how the microcatheter advances a long way, forming several loops. Nonetheless, the tip is quite far from the distal spot. Even in such a case, by using a 1:5 mixture we can achieve complete occlusion, as the glue travels distally enough to reach the spot. While copolymers are useful in many indications, they cause immediate reflux, which forces us to wait for

Arterial approach



33 yo female
Bleeding uterine AVM post-abortion




Figure 22 AB - 33 yo female - Bleeding uterine AVM post-abortion




Figure 22 - C: initial angio arterial, D: initial angio venous




Figure 22 - E: first feeder before embolization, F: first feeder after embolization




Figure 22 - G: second feeder before embolization, H: second feeder after embolization





Figure 22 - I: final control

the cast along the microcatheter to harden, in order to be able to push again. Besides, when the tip is too far, Onyx[®] or Squid simply cannot be pushed distally enough. Glue here poses no risks. Reflux on the catheter is a non-issue, as it will not prevent safe removal. Migration to capillaries is not common in case of AVMs such as, for example, a renal tumor. The case would be different with direct connections, for example a fistula. However, should you feel doubtful, you have the possibility of doing a test with Ethiodized Oil alone first. The final result shows patency of the main uterine artery with both branches correctly embolized. Microcatheter withdrawal can be performed while injecting, however this is not compulsory. In case of big arteries, we can place the tip in the main artery and use a highly diluted mixture. In other cases, if we have reasons to be selective and maintain the rest of the tumor bed patent, we can place the tip at the furthest point and inject while retracting. These are just two different options. Here, the several loops the microcatheter forms tell us we are very distal, however, even in case of reflux along the microcatheter, removing it will not be a problem. If we feel we are at the end-point and we need to leave the microcatheter in place for 30 seconds or so, there is no reason to worry, we can just proceed with the removal.

Cardiac hyperflow related dyspnea



Here is a case of cardiac hyperflow-related dyspnea (Figs.23-25) with a huge malformation in the inferior mesenteric artery. It is a typical AVM with a large dilation of the venous drainage. We started with a balloon-assisted embolization with Onyx[®] to slow down the flow, however, we soon realized the process was taking too long, and we agreed to use glue instead. This is due to the presence of many branches, which are easier and quicker to catheterize with glue. Thanks to the viscosity of the mixture, we have no passage to capillaries. The final result is rather good. The advantages to using glue in a case such as this are clearly visible. Employing mechanical agents is not an option here, as our goal is to reach the nidus. Big microparticles pose a high risk of recruitment of collaterals in such a long procedure. Glue, on the other



25 yo male
Cardiac hyperflow-related
dyspnea

Figure 23 - 25 yo male - Cardiac hyperflow-related dyspnea

Arterial approach



Balloon-assisted embolization to slow down
the flow in the IMA (1:2): 1st EVOH




Figure 24 AB



Figure 24 CD






Figure 24 EF



Selective glue injection of several feeding arteries...

Figure 25 AB





Figure 25 CD





Figure 25 EF

hand, is fast and risk-free. At CT scan we can observe thrombosis of the venous dilation and the distribution of the glue with no passage.

Endoleak type II

Here is a type 2 endoleak where arterial approach (Fig.26), though preferable in my opinion, proved impossible. In order to perform a percutaneous approach, we first insert a metal needle in which we place the microcatheter, to prevent high pressure reflux from pushing it out. We use an ordinary kit for biopsy or nephrectomy and insert a 17 G needle under fluoroscopic guidance at CT scan. We then place a valve at the proximal port of the needle to lock the 2.4 F microcatheter in place. This method will reduce the pressure of the reflux and leave us enough time to inject a 1:4 mixture with no risk of occluding the dead space and trigger early polymerization. While Onyx[®] might appear as a good indication in this case, we need to take into account the large number of artifacts, even though the amount of tantalum has been



Post-EVAR type 2 endoleak

Figure 26 - Post-EVAR type 2 endoleak

recently reduced in both Squid and Onyx®. At CT scan, we can observe a low quantity of artifacts after the procedure with Glubran®2 / Ethiodized Oil. Figure 27 shows an example of a type 2 endoleak A and B involving the inferior mesenteric artery, which is patent. In such cases, we usually start by accessing Riolo's arcade and then close the artery with coils, as the reflux would make deploying liquids challenging, if not impossible. As we can observe, the catheterism through the ilio-lumbar artery is quite complicated and we have extravasation, which does not allow to place the tip too distally. Nonetheless, this is not an issue. Just keep checking for dangerous collaterals and start injecting a 1:5/1:6 ratio mixture to reach the other side through reflux. Ensure both lumbar arteries are blocked, as well as the main nidus. Injection by direct puncture of the sack under CT guidance is not advisable, in our opinion, as triggering reflux in the lumbar arteries is not always an attainable goal and this may result in an incomplete embolization. We had a case in which we tried a transabdominal approach and injected the mixture




Figure 27 - Type 2 endoleak A and B

by direct puncture of the sack. We got reflux from a patent inferior mesenteric artery, which made us believe it was thrombosed but in fact it was not. Some glue migrated into the sigmoid branches. Fortunately, this brought no consequences for the patient, who was asymptomatic, however, the complications deriving by a cast of glue blocking the main trunk of the mesenteric artery can be disastrous. This is why it is crucial to check that the inferior mesenteric artery is occluded before injecting the mixture in the sack.

In a percutaneous approach, the dilution depends on the size of the artery. If it is big, choose a 1:4/1:5 ratio with a 3 ml syringe and a 2.4 F catheter. There is no need to keep injecting while retracting the catheter. You might need to prepare multiple syringes filled with mixture to ensure you have enough liquid to complete it. A fluoroscopy prior to the procedure may help to assess the outcome in advance. As previously mentioned, reflux in the main lumbar artery is not always attainable, so ensure the injection is performed very slowly in order to be able to correctly detect the endpoint.

The problem with injecting in the sack is that the liquid we are injecting causes engrossment and that is why it is difficult to understand when the end-point has been reached. The same will happen with copolymers. We usually inject 5 or 6 ml of Onyx® or Glubran®2, however, at times this quantity will not be enough.

False aneurysm

This is a false aneurysm of the hepatic artery (Fig.28) that we attempted to treat with a covered stent that was not well deployed. We found it impossible to retrieve the stent and still detect patency, which led us to successfully attempt a percutaneous approach with direct injection of glue in the pseudoaneurysm.

Angiomyolipoma

Benign tumors such as an angiomyolipoma are good example of glue embol-

False aneurysm of the hepatic artery




Figure 28 - False aneurysm of the hepatic artery




Figure 29 - Angiomyolipoma 1

lization (Fig.29). Here we have two main arteries for which we used a 1:5/1:6 ratio. We abundantly flushed using about 10 ml of dextrose solution and observed the drops of glue going distally until we got reflux. At that point, we stopped injecting and removed the microcatheter. In this kind of procedure, you have the possibility to check your progress step by step, which makes the procedure fast and neat, when compared to using microparticles. The same microcatheter may be reused after careful flushing with dextrose solution. Observe the even distribution of the agent. We recently published a paper on this procedure⁽⁵⁾. Figure 30 shows another example of a typical angiomyolipoma with a large hematoma and multiple aneurysms.

Having a single branch to intervene on makes this the perfect embolization. Use a 1:6 ratio and flush abundantly. Watch the glue go distally, wait for stasis and then for reflux. Stop injecting and retrieve the microcatheter. The whole process is very fast and simple when performed with glue. Microparticles are not a comparable alternative, as the same procedure would take



Figure 30 - Angiomyolipoma 2

about two hours to complete. Choosing the right size for the microparticles is a time-consuming decision as it is empirical and may need different tests. Besides, microparticles alone would not be enough to occlude the aneurysm, some other agent would have to be added at the proximal port or coils would have to be deployed after catheterizing each branch. Glue guarantees perfect results and can be used for both the distal and proximal embolization. Do not hesitate to flush abundantly using between 5 and 10 ml of dextrose solution.

Keep in mind that the highest the dilution, the biggest the quantity of mixture at our disposal.

When we employ a 1:1 ratio, the total amount of liquid amounts to 2 ml, which might not be enough for veins, PCS, or large varices in women. In those cases, remember to prepare in advance a few extra syringes already filled with mixture, as 2 ml would not be enough to completely occlude the pelvic reservoir and the main left ovarian vein.

Kidney pseudoaneurysm

Here we have a pseudoaneurysm in the kidney due to complications occurred after a partial nephrectomy (Fig.31). Placing the tip of the microcatheter at the bleeding site will allow to successfully conclude the procedure with as little as two drops of glue.

Choose a 1:3 dilution ratio, but keep in mind that these conditions allow for any ratio to work. Using coils might seem a safer choice here, however, the risk with coils is for the embolization to be more proximal than expected and to have to sacrifice a lot of collaterals to occlude the main branch. Glue represents a faster and safer choice, provided that we pay the proper attention.

Humeral bone metastasis

An example of a hypervascular humeral bone metastasis from kidney tumor (Fig.32). It is very similar to a high flow AVM and thus presents serious risk of venous passage, which discourages the use of microparticles.




Figure 31 - Pseudoaneurism of the kidney

We catheterized three branches using a 1:1 dilution ratio. Performing a test using Ethiodized Oil alone is a safe way to assess transvenous passage before the actual procedure. The cast of Glubran®2 in the different branches is clearly visible and the final result is extremely good. Using big microparticles in such an indication may appear as a valid option, however, time always represent an important factor to take into consideration. The embolization will take longer to complete, and it will very likely lead to recruitment of collaterals. Glue, on the other hand, will allow you to promptly cut the flow.

Tibial bone metastasis

Another case of hypervascular metastasis from kidney tumor prior to surgery for which we used a 1:5 dilution ratio (Fig.33). We can see the cast of glue perfectly occluding the two main branches of the popliteal artery. Once again, the procedure was completed in a remarkably short time. A randomized study from Portugal ⁽⁶⁾ has recently compared cyanoacrylates

Humeral bone metastasis




Figure 32 - Humeral bone metastasis: (A) before embolization; (B) after embolization.

Tibial bone metastasis





Figure 33 - Tibial bone metastasis: (A) before embolization; (B) after embolization.

with particles plus coils and concluded as follows: *“Portal vein embolization with N-butyl-cyanoacrylate plus iodized oil produced greater and faster liver growth as seen at CT in participants with liver cancer, compared with portal vein embolization with polyvinyl alcohol particles plus coils, allowing for earlier surgical intervention”* (Figs.34,35).

Previous studies also testified to the safety of using NBCA in portal vein embolization, as concluded by a 2018 systematic review and meta-analysis, which stated that: *“PVE utilizing NBCA to induce hypertrophy of the FLR prior to contralateral lobe resection in the setting of hepatic malignancy is safe and effective”* ⁽⁷⁾. Although particles and coils are widely used in this kind of procedure, not only are they extremely time-consuming, but the results are hardly comparable.

We used a standard contralateral approach from the right side. We first inserted a sheath, then a 5 F catheter in the main branch, and finally a micro-catheter, quite distally. Using a 1:8 dilution we started to inject the mixture



group ($P = .27$). Conclusion Portal vein embolization with *N*-butyl-cyanoacrylate plus iodized oil produced greater and faster liver growth as seen at CT in participants with liver cancer, compared with portal vein embolization with polyvinyl alcohol particles plus coils, allowing for earlier surgical intervention. © RSNA, 2021 *Online supplemental material is available for this article.* See also the

Randomized Controlled Trial > Radiology. 2021 Jun;299(3):715-724.
doi: 10.1148/radiol.202104055. Epub 2021 Apr 6.

BestFLR Trial: Liver Regeneration at CT before Major Hepatectomies for Liver Cancer—A Randomized Controlled Trial Comparing Portal Vein Embolization with *N*-Butyl-Cyanoacrylate Plus Iodized Oil versus Polyvinyl Alcohol Particles Plus Coils

José Hugo Mendes Luz¹, Filipe Veloso Gomes¹, Nuno Vasco Costa¹, Inês Vasco¹,
Ella Coimbra¹, Paula Mendes Luz¹, Hugo Pinto Marques¹, João Santos Coelho¹,
Raquel Maria Alexandre Mega¹, Vasco Nuno Torres Viçosa Ribeiro¹,
Jorge Tiago Rodrigues da Costa Lamelas¹, Maria Mafalda de Sampaio Nunes e Sobral¹,
Sílvia Raquel Gomes da Silva¹, Ana Sofia de Teixeira Carneira¹,
Susana Cristina Cardoso Rodrigues¹, António Augusto Ferreira Pinto de Figueiredo¹,
Margarida Varela Santos¹, Tiago Bilihim¹

Conference Abstract
https://doi.org/10.1148/202104055

C RSE CrossMark

REVIEW

Portal Vein Embolization Utilizing *N*-Butyl Cyanoacrylate for Contralateral Lobe Hypertrophy Prior to Liver Resection: A Systematic Review and Meta-Analysis

Ethan Wajnszajn¹, Tarik Jazmati², Sahil Contractor², Abhishek Kumar²

Figure 34 - Portal vein embolization




Figure 35 AB - Portal vein embolization.




Figure 35 CD



Figure 35 EF




Figure 35 GH

while removing the microcatheter at the same time in order to generate re-flux. As you may have noticed, this is a different technique that relies on re-flux to reach the other branches and complete the embolization. If needed, you can flush the catheter on the table and go back to embolize a different branch. The kind of embolization you will achieve using this method is very distal. Pay attention to the proximal port, especially when using a 1:8 ratio. An alternative is to prepare two different dilution rates, 1:8 for the distal port and 1:1 for the proximal port, although it is not necessary to embolize the proximal port. Concerning quantity, 9 ml is most likely enough in this case. The procedure is fast and easy and the result completely satisfactory. Flushing directly in the 5 F catheter is a possibility, provided that we make sure there is no glue on the tip lest we run the risk of leaving glue in the left port in the process of removing the catheter. A coaxial technique is always safer to manage.

The evidence from the randomized study has now proved that glue is the best embolic agent for portal vein embolization.

Gastrointestinal bleeding

Over the past five years, the literature concerning gastrointestinal bleeding shows that glue is the most often employed embolic agent in this kind of indication, especially in Asian countries⁽⁸⁻¹¹⁾. We have recently published a meta-analysis on the subject⁽²⁾.

How distal does Lower Gastrointestinal Bleedings (LGIB) need to be?

– Superselective

- Jejunum, ileum, colon
- Distal embolization of vasa recta (straight artery)
- Beyond the marginal artery
- As close as possible to the site of hemorrhage
- Bowel wall ischemia is unlikely
 - 3 or fewer vasa recta: not risky
 - 4 or more vasa recta: risky

In the discussion as to how to avoid ischemic complications (Fig.36), especially in relation to the lower gastrointestinal part, the factor that needs to be taken into account is the number of vasa recta we embolize. The risk is next to none when we embolize up to three vasa recta. In 2017, JVIR published a notable meta-analysis on the subject⁽³⁾.

The pooled clinical success and major complication rates in the 259 patients with UGIB in whom technical success was achieved were 82.1% and 5.4%, respectively, and those in the 175 patients with LGIB in whom technical success was achieved were 86.1% and 6.1%, respectively (Fig.37).

- 440 patients
- 13 ischemic complications: 2.9%
- Only 3 needed bowel resection (Fig.38)

- How distal does LGIB need to be?
 - Superselective
 - Jejunum, ileum, colon
 - Distal embolization of vasa recta (straight artery)
 - Beyond the marginal artery
 - As close as possible to the site of hemorrhage
 - Bowel wall ischemia is unlikely
 - 3 or fewer vasa recta: not risky
 - 4 or more vasa recta: risky

Hyun-Jin Joo, MD, Jin-Wook Chung, MD, Hyo-Chul Kim, MD, Young-Ha Na, MD, Hyung-Cheol Lim, MD, Wook Lee, MD, Byoung-Kwon Kim, MD, and Jae-Ryung Park, MD




Figure 36 - Avoiding ischemic complications

Transcatheter Arterial Embolization of Gastrointestinal Bleeding with *N*-Butyl Cyanoacrylate: A Systematic Review and Meta-Analysis of Safety and Efficacy

440 patients

13 ischemic complications: 2.9%

Only 3 needed bowel resection

Pt. No./Age/ Sex	Site of Bleeding	History of Bleeding	Embolic Agent	Embolic Agent LUGB	Anticoagulation	Management	Outcome
1/55F	Stomach	Ulceration	Histocryl	LGA	Ulcration	Conservative treatment	Recovered
2/90F	Stomach	Multigranuloma	Histocryl	LGA	Ulcration	Conservative treatment	Recovered
3/73M	Stomach	Ulceration	Histocryl	LGA	Ulcration	Conservative treatment	Recovered
4/73M	Duodenum	Ulceration	Histocryl, coils	GDA	Ulcer infection	Conservative treatment	Recovered
5/82M	Duodenum	Ischemic injury	Histocryl	APDA	Bowel infection	Conservative treatment	Death of perforation 6 wk later
1/75F	GJ anastomosis	Ischemic injury	Histocryl	JA	Ulcration	Conservative treatment	Recovered
2/68M	GJ anastomosis	Ischemic injury	Histocryl	JA	Bowel infection	Bowel resection	Recovered
3/56F	Jejunum	Multigranuloma	Histocryl	JA	Bowel infection	Conservative treatment	Recovered
4/58M	Appendix	-	Histocryl	AA	Bowel infection	Bowel resection	Recovered
5/50M	Appendix	Trauma	Histocryl	AA	Bowel infection	Bowel resection	Recovered
6/52M	Appendix	Diverticulosis	Histocryl	ICA	Bowel infection	Conservative treatment	Recovered
7/78M	Colon	Diverticulosis	Histocryl	ICA	Ulcration	Conservative treatment	Recovered
8/66M	Colon	Diverticulosis	Histocryl	ICA	Ulcration	Conservative treatment	Recovered

Figure 37




Figure 38

How to avoid ischemic complication

We can certainly say that there is no high risk of ischemic complications in the use of glue for this indication, disregarding the location.

If we look at the Cirse guidelines⁽¹²⁾, microcoils and particles are indicated as the most frequently employed embolic agents. In case of massive bleeding: "Glue or EVOH (copolymers) may be considered but with increased risk of ischemia". We believe this statement to be false, as the game-changing factor is in fact the number of vasa recta we embolize, not the embolic agent we choose. Additionally, severe ischemic complications requiring surgery are indicated as 4-5%, while the meta-analysis indicates in fact 2.9% (Fig.38).

We can conclude that, when compared to other embolic agents, in GI bleedings glue does not pose a higher risk of ischemic complications.

When we perform an empirical embolization, with or without extravasation, we can locate the bleeding ulcers through an endoscopy and then proceed with embolizing the gastroduodenal artery (GDA) (Figs.39-41).

Gastric bleeding




Figure 39

Duodenal bleeding




Figure 40




Figure 41

We usually put coils in the right gastroepiploic artery (GEA) to protect it and prevent distal embolization by liquids. It is now safe to inject the glue in the rest of the trunk and the branches. Because we need to avoid migration in case of reflux, we use a 1:1 dilution ratio and start to form the cast by slowly injecting the mixture while removing the microcatheter. We published many papers on GDA bleeding, showing that it is always preferable to use a combination of agents, however, when only one embolic agent is employed, glue gives the best results.

Extravasation control

It is important to always check the superior mesenteric artery for extravasation. With so many collaterals, there is no danger of ischemic complications, however, an incomplete embolization may pose serious risk of rebleeding, as most of these patients have comorbidities or take anticoagulants. For this reason, we perform a very aggressive embolization in these cases, to ensure

we will not need to intervene a second time at a later stage.

Whether we were dealing with recanalization or with a known event previously shown by the initial angiography, the extravasation was evident and made it difficult to approach more distally. We used a 1:3/1:4 ratio and achieve great results. Regarding a left colon extravasation from the inferior mesenteric artery, the risk of recanalization is high, as it is impossible to reach behind the extravasation to perform a sandwich embolization with the aid of coils. This is what we call a blocked flow embolization, where glue is the perfect choice as it allows for total control.

The mixture will advance when we push and it will stop when we stop injecting. By using hyperpressure, we can easily push the glue beyond the extravasation point and reach the two vasa recta we need to embolize. The feeling is that of a microcatheter with an occlusive balloon: we want to avoid reflux so we push slowly and distally. We do not actually need a balloon, the microcatheter is enough to block the flow, as you can see in this case of diverticular bleeding (Fig.42). This is another example of extravasation from trauma, in a spastic patient (Fig. 43)⁽¹³⁾. The artery is small and the extravasation quite large, however, we can sacrifice the branch without concern. Two drops of glue are enough here and the the dilution ratio is not important. Due to the spasticity and the bleeding, it is easy to underestimate the size of the coils and cause the artery to reopen at a later time. Figures 44 A-F show a complicated case of hepatocellular carcinoma (HCC) bleeding with occlusion of the celiac trunk involving the superior mesenteric artery and the pancreatic duodenal arcades. Chemoembolization would appear the perfect step to follow such a procedure, however, it is not necessary. The patient can be fully treated through a simple embolization performed by using a 1:6 dilution ratio, and closing the access for any future chemoembolization will not be an issue. At follow-up, we observed perfect necrosis and the patient was admitted for surgery. After five years, the patient is alive and doing well. In this particular indication, the chemotherapeutic agent in chemoembolization is only accessory to the embolization itself, and you can sacrifice the branch with-

Diverticular bleeding




Figure 42 - Diverticular bleeding

20 year-old woman, trauma





Figure 43 - 20 year-old woman, trauma



HCC rupture

Figure 44 AB - HCC rupture




Figure 44 CD




Figure 44 EF

out concern and achieve the best possible outcome. In case of pseudoaneurysm in the splenic artery, we know we can expect an infarction as a likely consequence, disregarding the embolic agent of choice. Nevertheless, the size of the infarction may be affected by the number of microcoils employed to complete the embolization. Once again, liquids appear to be the safest solution. Recently, patients on anticoagulants who arrive in our practice with spontaneous bleeding have been more and more frequent; this is a complicated indication, as we cannot treat the patient directly, but we have to rely on images⁽¹⁴⁾. Sometimes, we can only detect a small hematoma and the patient seems to be recovering well, however, the size of the hematoma represents a prognostic factor in itself. In case of internal extravasation, we find that the best choice is to perform a preventive embolization, as the hematoma is likely to grow, causing both venous and arterial bleeding that are not easy to control when it is too late. By using a 1:3/1:4 dilution ratio we can perform a quick embolization and sacrifice the entire branch to prevent complications that can take

as little as one hour to arise. Undoubtedly, age is an important factor in the rate of the growth and we are aware that this is more likely to happen in patients who are over 70 years old. Nonetheless, if the CT scan detects an active bleeding with extravasation, we do not foresee it is likely to stop spontaneously. Even when we decide to administer antagonists, for example, we know they take several hours to work, so we proceed with embolizing at the same time, to prevent the hematoma from growing. In 50 patients who underwent Glubran® 2 embolization, we observed a 40% mortality rate at one month: clinicians are possibly unaware of such outcome and often put patients on anti-coagulant even when they are not strictly necessary. While these medications can save lives, they can also cause death. In patients who are being treated with antiplatelet or anticoagulant, we see spontaneous bleeding in absence of trauma, and the hematoma grows bigger every time. At least in case of extravasation, preventive embolization is, in our opinion, the safest choice, even when the patient conditions seem to be improving (Fig. 45)⁽¹³⁾.




Figure 45

Prostatic embolization

A very interesting indication we recently published about is **prostatic artery glue embolization for adenoma** (Figs. 46-49) ⁽¹⁵⁻¹⁷⁾.

We tried to create a blocked flow environment and that is why we preferred a 2.7 F microcatheter. We positioned the tip as far as possible and then injected a 1:8 ratio mixture. Observe the cast travelling distally and the even distribution. This is a 50 patients safety study and, from a clinical perspective, the results are comparable to those indicated by the literature on the use of microparticles.

I personally recently reviewed a paper about a retrospective study on particle embolization versus glue embolization. While the complication rate derived by the use of glue was not considerably lower, what was significant was the difference in radiation exposure. This is due to the simple fact that glue embolization is a much faster procedure. Naturally, catheterism is the most challenging part of this kind of procedure, disregarding the agent of choice, but embolization with microparticles takes about 15 minutes for each side, whereas glue only takes a few seconds to work, and that significantly reduces radiation exposure. Moreover, when we have collaterals, we do not want to embolize, we can occlude them with a cast of glue and push again in the gland, which is not possible with particles. In some cases, if we cannot occlude the proximal port of the collaterals with coils, we cannot perform the embolization. **Glue will work in any situation, especially in a blocked flow scenario**, because when you push some glue very slowly at the proximal port of the collateral and then wait a short time, you will be able to push again in the main branch into the gland with no risk of penile non-target embolization.

Article

Prostate Artery Embolization Using N-Butyl Cyanoacrylate Glue for Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Valid Alternative to Microparticles?

Romain Loeffroy ^{1,*}, Kevin Guillen ², Etienne Sait ³, Clément Marcolin ³, Pierre-Olivier Comby ³, Marco Midulla ³, Nicolas Grenier ³, Olivier Chevallier ³ and François Petitpierre ²

¹ Department of Vascular and Interventional Radiology, Image-Guided Therapy Center, François-Mitterrand University Hospital, 14 Rue Paul-Gustave, BP 7706, 21079 Dijon, France; kguillen@univ-dijon.fr (K.G.); rmidulla@univ-dijon.fr (M.M.); ochevallier@univ-dijon.fr (O.C.)
² Department of Interventional Radiology, Pellegrin University Hospital, Place Aurore-Robert-Louis, 33076 Bordeaux, France; etienne.sait@univ-bordeaux.fr (E.S.); clement.marcolin@univ-bordeaux.fr (C.M.); nicolas.grenier@univ-bordeaux.fr (N.G.); petitpierre.fr@univ-bordeaux.fr (F.P.)
³ Department of Neuroradiology and Emergency Radiology, François-Mitterrand University Hospital, 14 Rue Paul-Gustave, BP 7706, 21079 Dijon, France; pcomby@univ-dijon.fr (P.-O.C.)
 * Correspondence: romain.loeffroy@univ-dijon.fr; Tel.: +33-380-295427

Table 3. PAE efficacy outcomes after 3 months.

Variables	Baseline	3 Months	Change (%)	p Value
IPSS				
Mean ± SD	20.5 ± 6.7	9.9 ± 6.8	−10.6 (51.7)	0.0001
Median (IQR)	20.5 (16.7–25)	8.0 (5.3–13.0)	−12.5 (61.0)	
QoL score				
Mean ± SD	4.9 ± 1.0	2.2 ± 1.5	−2.7 (55.1)	0.0001
Median (IQR)	5.0 (4.0–6.0)	2.0 (1.0–3.0)	−3 (60.0)	
IIIEF5				
Mean ± SD	16.2 ± 7.5	15.8 ± 7.9	−0.4 (2.5)	0.078
Median (IQR)	17.5 (11.0–23.0)	18.0 (10.0–23.0)	+0.5 (2.8)	
PSA (ng/mL)				
Mean ± SD	6.4 ± 3.7	4.6 ± 3.0	−1.8 (28.1)	0.0001
Median (IQR)	5.6 (4.0–7.6)	4.1 (2.3–5.9)	−1.5 (26.8)	
Prostate volume (mL)				
Mean ± SD	98.3 ± 40.2	77.3 ± 30.5	−21 (21.4)	0.0001
Median (IQR)	91.2 (67.6–122.3)	70.7 (57.7–94.6)	−20.5 (22.5)	

IQR, interquartile range; IPSS, International Prostatic Symptoms Score; QoL, quality of life; IIIEF5, International Index of Erectile Function; PSA, prostate-specific antigen. p values < 0.05 were considered statistically significant.

Figure 46




Figure 47



Figure 48




Figure 49

Varicocele

In another study we compared different groups using several embolic agents, such as Glubran® 2, polidocanol, and coils (Fig. 50)⁽¹⁸⁾. Our study concluded as follows: “*The use of Glubran® 2 acrylic glue for varicocele embolization is safe and leads to less radiation and lower recurrence rates than is the case for other embolic materials without any more significant pain*” (Figs. 51, 52)⁽¹⁹⁾. This is a typical distal embolization performed with a 5 F catheter. As shown in the picture, the standard goal is usually to embolize from point A to point B, which we believe is a mistake, since revascularization and recurrence always involve the saphenous branch below the iliopectineal line. Disregarding the difference in branches, we always have anastomosis behind this point, and this is why we prefer to embolize from point C to point A. We place the microcatheter at point C and start injecting a 1:1 ratio mixture while retracting the microcatheter until the embolization is complete and we can remove it. When it is not possible to place the microcatheter far enough, we can exploit the features of liquids by placing the tip at point A and ask the patient for Valsalva. This will help the glue to travel distally, all the way down to point C. In case of reflux at the tip, make sure you do not immediately remove the microcatheter, but wait for polymerization to start and withdraw the microcatheter after about 5 minutes⁽²⁰⁾.

Article

Relevant Biological Effects of Varicocele Embolization with N-Butyl Cyanoacrylate Glue on Semen Parameters in Infertile Men

Olivier Chevallier ^{1,2}, Patricia Fauque ³, Carole Poncelet ⁴, Kévin Guillen ^{1,2}, Pierre-Olivier Comby ^{2,4}, Karine Astruc ⁵, Julie Barberet ⁶, Nicolas Falvo ⁵, Emmanuel Simon ⁷ and Romaric Loeffroy ^{1,2,4}




Figure 50

Original Article

Comparison of three different embolic materials for varicocele embolization: retrospective study of tolerance, radiation and recurrence rate

Nicolas Favard¹, Morgan Moulia¹, Patricia Fauque¹, Aurélie Bertaut¹, Sylvain Favelier¹, Louis Estivalet¹, Frédéric Michel¹, Luc Cormier¹, Paul Sagot¹, Romaric Loeffroy^{1,2}

Background: To evaluate pain, radiation and recurrence rates in patients undergoing varicocele embolization with three different embolic materials.

Methods: Retrospective study of 182 consecutive patients who underwent transcatheter retrograde varicocele embolization from July 2011 to May 2015 with glue (Gluhan®2) (group 1, n=63), mechanical agents (coils and/or plugs) (group 2, n=53) or a sclerosing agent (polidocanol) (group 3, n=66). Patients were asked by telephone interview to evaluate pain during embolization and at 1, 7 and 30 days using a quantitative pain scale ranging from 0 to 10. Duration of scopy, kinetic energy released per unit mass (kema) and dose area product (DAP) were assessed as radiation parameters during embolization procedures. Recurrence rates after treatment were also evaluated. Statistical analyses were performed using parametric and non-parametric tests.

Results: Patients in the three study groups were comparable for age, clinical indication and embolization side. No difference was noted for significant pain (pain score ≥3) during embolization and at 1, 7 and 30 days after treatment. Discomfort (pain score <3) was more frequent in group 1 than in groups 2 and 3 at 7 days after the procedure (P=0.049). No difference in discomfort was noted during embolization or at 1 and 30 days. Duration of scopy was shorter (P<0.0001) and kema was lower (P=0.0087) in group 1 than in groups 2 and 3. DAP was lower in group 1 than in group 2 (P=0.04) but no difference was noted between groups 1 and 3, and groups 2 and 3. The recurrence rate at a mean follow-up of 24.4 months (range, 2–53 months) was significantly lower in group 1 than in the two other groups (P=0.032).

Conclusions: The use of Gluhan®2 acrylic glue for varicocele embolization is safe and leads to less radiation and lower recurrence rates than is the case for other embolic materials without any more significant pain.

Figure 51

**Below potential collaterals:
saphenous/hypogastric veins**




Figure 52

Pelvic congestion syndrome (PCS): connection with internal iliac artery (IIA)

The goal in this case is to embolize the reservoir in order to achieve a distal embolization (Fig. 53). The steps here are to first put one or two coils at the proximal port, go through the coils with the microcatheter, inject the glue from the distal port, and ask the patient for Valsalva while removing the catheter until we reach the coils.

In women varices are normally very large and the cast of glue in case of reflux can be less easily controlled so we use the coils not to occlude but to protect. A possible reflux would be trapped by the coils.

PCS: connection with IIA



Figure 53

False aneurysm at the common femoral artery

Here we have a false aneurysm at the common femoral artery (Figs.54,55). In this case we need additional access, as it is mandatory to place a balloon in front of the neck in order to prevent reflux that would be seriously difficult to handle.

After placing the balloon, we inject the glue directly in the sack using the metallic needle and, under fluoroscopy, we fill the sack using a 1:1 mixture. We wait about 5 minutes before deflating the balloon. Always perform a thorough check to ensure nothing is left in the artery. A 0.035" balloon poses no risk of sticking or bursting (Fig.56).



Figure 54




Figure 55




Figure 56

Conclusions

In conclusion, **liquids have proved extremely useful and versatile, despite the learning curve.** We have assessed that the risk rate for non-target embolization or reflux is comparable to using microparticles. As this is a one-shot embolization, we need to be confident.

The goal of this workshop is chiefly to dispel any doubt related to sticking the catheter: do not fear a little extra adherence, as this is not a real issue.

Among the many agents at our disposal, **the combination Glubran®2 / Ethiodized Oil has proved to be the fastest and easiest option in many indications.**

Take home messages

- **Very useful but underutilized embolic agent**
- Sometimes challenging to use
- **However, in many situations, glue is the best choice**
- Familiarity with glue injection is preferable
- Steep learning curve... as with any embolic agent!
- Pay attention to non-target embolization

References

1. Loffroy R, Guiu B, Cercueil JP, Krausé D. Endovascular therapeutic embolisation: an overview of occluding agents and their effects on embolised tissues. *Curr Vasc Pharmacol.* 2009;7(2):250-63.
2. Chevallier O, Comby PO, Guillen K, et al. Efficacy, safety and outcomes of transcatheter arterial embolization with N-butyl cyanoacrylate glue for non-variceal gastrointestinal bleeding: a systematic review and meta-analysis. *Diagn Interv Imaging.* 2021;102(7-8):479-87.
3. Comby PO, Guillen K, Chevallier O, et al. Endovascular use of cyanoacrylate-lipiodol mixture for peripheral embolization: properties, techniques, pitfalls, and applications. *J Clin Med.* 2021;10(19):4320.
4. Prigent FV, Guillen K, Comby PO, et al. Selective arterial embolization of renal angiomyolipomas with a N-butyl cyanoacrylate-lipiodol mixture: efficacy, safety, short- and mid-term outcomes. *J Clin Med.* 2021;10(18):4062.
5. Luz JHM, Veloso Gomes F, Costa NV, et al. BestFLR Trial: liver regeneration at CT before major hepatectomies for liver cancer - a randomized controlled trial comparing portal vein embolization with N-butyl-cyanoacrylate plus iodized oil versus polyvinyl alcohol particles plus coils. *Radiology.* 2021;299(3):715-24.
6. Wajswol E, Jazmati T, Contractor S, Kumar A. Portal vein embolization utilizing N-butyl cyanoacrylate for contralateral lobe hypertrophy prior to liver resection: a systematic review and meta-analysis. *Cardiovasc Intervent Radiol.* 2018;41(9):1302-12.
7. Frodsham A, Berkmen T, Ananian C, Fung A. Initial experience using N-butyl cyanoacrylate for embolization of lower gastrointestinal hemorrhage. *J Vasc Interv Radiol.* 2009;20(10):1312-9.
8. Mine T, Murata S, Nakazawa K, et al. Glue embolization for gastroduodenal ulcer bleeding: contribution to hemodynamics and healing process. *Acta Radiol.* 2013;54(8):934-8.
9. Loffroy R. Transcatheter arterial embolization for gastroduodenal ulcer bleeding: the use of cyanoacrylate glue has gained acceptance. *Acta Radiol.* 2014;55(3):325-6.
10. Hur S, Jae HJ, Lee M, et al. Safety and efficacy of transcatheter arterial embolization for lower gastrointestinal bleeding: a single-center experience with 112 patients. *J Vasc Interv Radiol.* 2014;25(1):10-9.
11. Kim PH, Tsao J, Shin JH, Yun SC. Transcatheter arterial embolization of gas-

- trointestinal bleeding with N-butyl cyanoacrylate: a systematic review and meta-analysis of safety and efficacy. *J Vasc Interv Radiol.* 2017;28(4):522-531.e5.
12. Valek V, Husty J. Quality improvement guidelines for transcatheter embolization for acute gastrointestinal nonvariceal hemorrhage. *Cardiovasc Interv Radiol.* 2013;36:608-12.
 13. Abdulmalak G, Chevallier O, Falvo N, et al. Safety and efficacy of transcatheter embolization with Glubran®2 cyanoacrylate glue for acute arterial bleeding: a single-center experience with 104 patients. *Abdom Radiol (NY).* 2018;43(3):723-33.
 14. Jawhari R, Chevallier O, Falvo N, et al. Outcomes of transcatheter arterial embolization with a modified N-butyl cyanoacrylate glue for spontaneous iliopsoas and rectus sheath hematomas in anticoagulated patients. *J Vasc Interv Radiol.* 2018;29(2):210-7.
 15. Loffroy R, Guillen K, Comby PO, Chevallier O. Prostate artery embolization using N-butyl cyanoacrylate glue for urinary tract symptoms due to benign prostatic hyperplasia: a valid alternative to microparticles? *Cardiovasc Interv Radiol.* 2022;45(6):824-5.
 16. Salet E, Crombé A, Grenier N, et al. Prostatic artery embolization for benign prostatic obstruction: single-centre retrospective study comparing microspheres versus n-butyl cyanoacrylate. *Cardiovasc Interv Radiol.* 2022;45(6):814-23.
 17. Loffroy R, Guillen K, Comby PO, Chevallier O. Prostate artery embolization for benign prostatic hyperplasia: rationale for the use of n-butyl cyanoacrylate glue as an embolic agent. *Cardiovasc Interv Radiol.* 2022 Jun;45(6):824-5.
 18. Favard N, Moulin M, Fauque P, et al. Comparison of three different embolic materials for varicocele embolization: retrospective study of tolerance, radiation and recurrence rate. *Quant Imaging Med Surg.* 2015;5(6):806-14.
 19. Chevallier O, Fauque P, Poncelet C, et al. Relevant biological effects of varicocele embolization with n-butyl cyanoacrylate glue on semen parameters in infertile men. *Biomedicines.* 2021;9(10):1423.
 20. Chevallier O, Fauque P, Poncelet C, et al. Relevant biological effects of varicocele embolization with N-butyl cyanoacrylate glue on semen parameters in infertile men. *Biomedicines.* 2021;9(10):1423.

for endovascular use: indications and techniques

[illegible]

for endovascular use: indications and techniques

[illegible]

SIX PRODUCTS IN A DROP.



ADHESIVE

High tensile strength. Acceptable minimum load is $\geq 435 \text{ N}$ [approx. 18 Kg/cm²].²⁻³



SEALANT

Applied with dedicated nebulizing devices it forms a thin film with sealing and waterproof properties due to its synthetic nature and strong adhesive power.³⁻⁶



HAEMOSTATIC

Effective in wet environment.¹⁰



BACTERIOSTATIC

Blocks bacterial growth for an average of 7 days.¹⁰⁻¹²



SCLEROSANT

Injected into the lumen of a vessel/varices, polymerize generating a plastic cap causing thrombosis and subsequent fibrosis and sclerosis.¹³⁻¹⁷





LIQUID EMBOLIZING AGENT²⁰⁻⁸¹

Injected into a blood vessel polymerizes building a cast adheres to the vessel occluding it such as an embolus. It causes completely and definitively occlusion without any recanalization, equivalent to surgical ligation.

Tailored dilutions with Ethiodized Oil allow a great modulability of Glubran[®] 2, adaptable to a large variety of cases:

TREATMENTS	GLUBRAN [®] 2/Ethiodized Oil
• Arterial and venous bleeding	1:3-1:6 ^{48,57,58, 84}
• AVM	1:3 ⁸⁴
• Fistulas	1:1-1:3 ^{24,30,36,46,62,73,79}
• Varicocele	1:1 ⁸⁴
• Cysts and tumours	1:1-1:6 ^{29,31,67}
• Portal Vein	1:1-1:8 ⁸⁴
• Endoleaks type II	1:3 ^{41,49,56}

- Ready to use
- Does NOT polymerise in the presence of air
- Storage at +2 to +8°C
- Can remain at room T (22,5 +/- 2,5°C) per 48h ²



The co-monomer NBCA + MS is an add value to give:

- Polymerisation Temperature: 45°C lower than 80-90 °C typical of pure monomeric cyanoacrylates like N-Butyl-CyanoAcrylate and Hesiyl-Cyanoacrylate¹⁰⁻¹³⁻⁶¹⁻⁸²
- NO tissue necrosis¹⁰⁻¹²⁻⁶¹⁻⁶³⁻⁶⁴
- Greater elasticity of the cast at the end of the polymerization⁴⁻⁶

Appearance

TRANSPARENT

Odour

TYPICAL OF CYANOACRYLATES

Density

SIMILAR TO WATER

GUIDELINES FOR USING GLUBRAN[®] 2



1. Careful preliminary angiographic examination

Identification of the afferent and collateral vessels and any eventual AV fistulas, with oblique and cranio-caudal projections



2. Selective and superselective catheterisation of the area to be embolised




3. Careful hemodynamic evaluation



4. Dilute with Lipiodol[®]:

- To delay the Glubran[®] 2 to polymerisation start time
- To make it radiopaque



5. Mix the two compounds uniformly

Immediately before injection (with a 3-way resistant stopcock or in a steel bowl)



6. Wash the catheter with glucose or dextrose solution



7. Inject slowly

- A single injection continuously



- Multi-shot or "sandwich" technique: push the mixture with glucose/dextrose



8. Remove the catheter

(quickly and immediately after the injection, if it was not performed the "sandwich technique" with glucose)



9. Eventual check with contrast medium at least two minutes later

WARNING: DO NOT USE GLUBRAN[®] 2 WITH POLYCARBONATE OR SILICONE MATERIALS

Advised products & materials

- Glubran[®] 2/Lipiodol[®] Ultra-Fluid
- Glucose or dextrose 5%-33%
- Polyethylene (PE) or polypropylene (PP) syringes with luer lock
- 3-way-stopcocks
- Standard 4F catheter
- Coaxial microcatheter

Glubran[®] 2/Lipiodol[®] dilution ratios⁸⁴

	MICROCATHETER POSITION	CATHETER TIP	INJECTION OF THE MIXTURE	FLOW SPEED	OCCCLUSION	EXAMPLES OF APPLICATIONS
GLUBRAN [®] 2/LIPIODOL [®] 84 Dilution ratio 1:1 to 1:3 ¹⁻⁷	Close to lesion	Wedged	Continuous	High	Proximal	Varicocele, Hypervascularized tumors, Gastro-intestinal bleedings, Peripheral bleedings, Pseudoaneurysms, High-flow AVM
GLUBRAN [®] 2/LIPIODOL [®] 84 Dilution ratio 1:4 to 1:9 ¹⁰⁻¹⁴	Far from lesion	Free	Drop by drop	Low	Distal	Organ-end artery, Portal vein embolization, Low-flow AVM, Tumor devascularization, Venous malformations, Lymphatic leakage

1. Loffroy R, Glubran 2. Histoacryl or TruTik. Which cyanoacrylate glue for endovascular use? *Diagn Interv Imaging*. 2016 Jan;97(1):119.
2. Soldani G. Valutazione della Biocompatibilità del Dispositivo Medico Chirurgico di Classe III: Glubran 2. Laboratory for Biomaterials & Draft Technology-Istituto di Fisiologia Clinica del CNR Creas- Malattie Cardiovascolari e Discipline Affini, MASSA, Italy, 1998. Internal GEM data file.
3. Kuli S, Martignelli J, Briganti E, Losi P, Spiller D, Tonello S, Soldani G. Glubran 2 surgical glue: *in vitro* evaluation of adhesive and mechanical properties. *J Surg Res*. 2009 Nov;157(1):e15-21.
4. Davoli F, Selliti F, Brandolini J, Dolci G, Castagnoli A, Bedetti B, Stella F. Use of coagulant spray glue (Glubran 2) for aorticospastic processes in pulmonary parenchyma resections in pigs: a preliminary study. *Eur Surg Res*. 2009;43(4):360-4.
5. Esposito C (1997) L'utilisation d'une nouvelle colle chirurgicale en chirurgie laparoscopique: quels avantages? *J Coloproctol* 3:68-66
6. Parat J, Lochman P, Blazek S, Pavlik M. Glued versus stapled anastomosis of the colon: an experimental study to determine comparative resistance to intraluminal pressure. *Asian J Surg*. 2014 Jul;37(3):154-61.
7. Esposito C, Damiano R, Settimi A, De Marco M, Maglio P, Centonze A. Experience with the use of tissue adhesives in pediatric endoscopic surgery. *Surg Endosc*. 2004 Feb;18(2):290-2. Epub 2003 Dec 29. Review.
8. Cipolletta L, Zambelli A, Bianco MA, De Grazia G, Meucci C, Lupinacci G, Salerno R, Piscopo R, Marmo R, Orsini L, Rotondano G. Acrylic glue injection for acute bleeding oesophageal varices: A prospective cohort study. *Dig Liver Dis*. 2009 Oct;11(10):729-34.
9. Grassi R, Capone P, Iritano E, Viero K, Caretti F, Martinotti M, Rozzi G, Buffoli F. Non-variceal upper gastrointestinal bleeding. Rescue treatment with a modified cyanoacrylate. *World J Gastroenterol*. 2016 Dec 28;22(48):10609-10616.
10. Losi P, Burchielli S, Spiller D, Finotti V, Kuli S, Briganti E, Soldani G. Cyanoacrylate surgical glue as an alternative to suture threads for mesh fixation in hernia repair. *J Surg Res*. 2010 Oct;163(2):e53-8.
11. Karatepe O, Ozturk A, Koculu S, Cagatay A, Kamal G, Aksoy M. To what extents cyanoacrylate of use to prevent early wounds infections in hernia surgery? *Hernia*. 2008 Dec;12(6):603-7.
12. Howell JN, Bresnahan KA, Stein TD, Hindsda HS, Edwards BA (1995) Comparison of effects of suture and cyanoacrylate tissue adhesive on experimental incisional lacerations. *Antimicrob Agents Chemother* 39:559-560
13. Montanaro L, Arciola CR, Cenni E, Caglietti G, Savio F, Filippini F, Barsanti LA. Cytotoxicity, blood compatibility and antimicrobial activity of two cyanoacrylate glues for surgical use. *Biomaterials*. 2001 Jan;22(1):59-66
14. Sáenz de Miera Rodríguez A, Baltar Arias R, Vázquez Rodríguez S, Díaz Saa J, Ulla Rocha JL, Vázquez-Saúluis J, Vázquez Astay E. N-Butyl-2-cyanoacrylate plug on fundal varix: persistence 3 years after sclerotherapy. *Rev Esp Enferm Dig*. 2009 Oct;101(3):212-4.
15. Seewald S, Siram PV, Naga M, Fennerty MB, Boyer J, Oberst F, Soehendra N. Cyanoacrylate glue in gastric variceal bleeding. *Endoscopy*. 2002 Nov;34(11):926-32.
16. Seewald S, Seitz U, Yang AM, Soehendra N. Variceal bleeding and portal hypertension: still a therapeutic challenge? *Endoscopy*. 2001 Feb;33(2):126-39.
17. Battaglia G, Bocas P, Merigiano S, Morlin T, Carta A, Coppa F, Rampado S, Ancona E. Les aspects endoscopiques de l'hypertension portale: diagnostic et classification. *Acta Endoscopica*. 2000 Dec;30(5):537-554.
18. Seewald S, Ponnudurai R, Jackle S, Thonke F, Soehendra N. Traitement endoscopique de l'hémorragie par rupture de varices. *Acta Endoscopica*. 2000 Dec;30(5):511-517.
19. Battaglia G, Morlin T, Patarnello E, Carta A, Coppa F, Ancona A. Diagnostic et traitement endoscopique des varices gastriques. *Acta Endoscopica*. 1999 Apr;29(2):97-114.
20. Favard N, Moulin M, Fauque P, Bertalet A, Faveller S, Estivalte L, Michel F, Cormier L, Sagot P, Loffroy R. Comparison of three different embolic materials for varicocoe embolization: retrospective study of tolerance, radiation and recurrence rate. *Quant Imaging Med Surg*. 2015 Dec;5(6):806-14.
21. Poretto D. Trattamento delle telangiectasie arteriole post-chirurgiche con iniezione imaging-guidata di colla a base di cianocrilato modificato. Abstract from "Proceedings XXVIII Congress Soc. Ed. Edizioni Internazionali, pag.11-14.
22. Loffroy R. Using Glubran 2 acrylic glue to maximize results of transcatheter arterial embolization for refractory upper gastrointestinal bleeding. *Scand J Gastroenterol*. 2015;50(10):1306-7.
23. San Norberto EM, Brizuela JA, Revilla A, Taylor JH, Vaqueiro C. Endovascular embolization of a muscular symptomatic arteriovenous malformation with Glubran 2 acrylic glue. *Vascular*. 2015 Aug;23(4):432-5.
24. López J, Rodriguez K, Targarella EM, Guzman H, Corral J, Gameros R, Reyes A. Systematic review of cyanoacrylate embolization for refractory gastrointestinal stasis: a promising therapy. *Surg Innov*. 2015 Feb;22(1):88-96.
25. Rebonato A, Auci A, Sanguinetti F, Maletti D, Rossi M, Brunese L, Carratello G, Torri T. Embolization of the perigastric venous plexus for erectile dysfunction resulting from venous leakage. *J Vasc Interv Radiol*. 2014 Jun;25(6):866-72.
26. Marcello R, Marcello G. Glubran 2 Transcatheter Embolization of Arterial Gastrointestinal Hemorrhage. International symposium on endovascular therapy. 2014; January 18-22.
27. Urbano J, Cabrera M, Alonso-Burgo A. Sclerosis and varicocoe embolization with N-butyl cyanoacrylate: experience in 41 patients. *Acta Radiol*. 2014 Mar;55(2):179-85.
28. Del Corso A, Vergaro G. Percutaneous treatment of iatrogenic pseudoaneurysms by cyanoacrylate-based wall-plug. *Cardiovasc Interv Radiol*. 2013 Jun;36(3):669-75.
29. Rossi G, Mavrogenis AF, Casadei R, Bianchi G, Romagnoli C, Rimondi E, Ruggieri P. Embolisation of bone metastases from renal cancer. *Radiol Med*. 2013 Mar;118(2):293-302.
30. Mauri G, Sconza LM, Fiore B, Brambilla G, Pedicini V, Poretto D, Luttman RF, Montorsi M, Sardanelli F. Post-surgical internal fistula treatment with imaging-guided percutaneous injection of cyanoacrylic glue. *Cardiol*. 2013 Jan;58(1):59-63.
31. Rossi G, Mavrogenis AF, Rimondi E, Ciccarese F, Tranfaglia C, Angeli B, Fiorentini G, Bartalena L, Erani C, Ruggieri P, Mercuro M. Arterial embolisation for bone tumours: experience of 45 cases. *Radiol Med*. 2011 Aug;116(5):793-808.
32. Rossi G, Angelini A, Mavrogenis AF, Rimondi E, Ruggieri P. Successful treatment of aneurysmal bone cyst of the hip in a child by selective transcatheter arterial embolization. *J Vasc Interv Radiol*. 2010 Oct;21(10):1591-5.
33. Chandra J, Anthony S, Ueberl R. Embolization of the internal iliac artery with Glubran 2 acrylic glue: initial experience with an adjunctive uterine occlusive agent. *J Vasc Interv Radiol*. 2010 Jul;21(7):1109-14.
34. Rossi G, Rimondi E, Bartalena T, Gerardi A, Alberghini M, Staats EL, Erani C, Bianchi G, Toscano A, Mercuro M, Vanel D. Selective arterial embolization of 36 aneurysmal bone cysts of the skeleton with N-2-butyl cyanoacrylate. *Skeletal Radiol*. 2010 Feb;39(2):161-7.
35. Loffroy R, Guib B. Role of transcatheter arterial embolization for massive bleeding from gastroduodenal ulcers. *World J Gastroenterol*. 2008 Dec;14(24):5809-17.
36. Pedicini V. Treatment of postoperative enteric fistulas through percutaneous image-guided injection of Glubran 2. XXVIII SPIC National Congress - Varese, 22-24 March 2017
37. Urbano J, Cabrera M, Alonso A. Usage and applicability of Cyanoacrilic monomer: further vascular malformations. e-Poster. P-1573 Congress: CIRSE 2008
38. Loffroy R, D'Atis P, Mezzetta L, Gagnaire A, Jouve JL, Ortega-Deballon P, Cheynel N, Cerceul JP, Krause D. Arterial embolotherapy for endoscopically unmanageable acute gastroduodenal hemorrhage: predictors of early relapse. *Clin Gastroenterol Hepatol*. 2009 May;7(5):515-23.
39. Lauterio A, Sili A, Aseni P, Giacomoni A, Di Sandro S, Corso R, Mangoni I, Mihaylov P, Al Kafahi M, Proetta V, De Carlis L. Percutaneous Transcatheter Bleed Duct Ablation with N-Butyl Cyanoacrylate in the Treatment of a Biliary Complication after Split Liver Transplantation. *J Transplant*. 2009;2009:824083.
40. Gandini R, Angelopoulou G, Konda D, Messina M, Chiochi M, Perretta T, Simonetti G. Transcatheter embolization of a large symptomatic pelvic arteriovenous malformation with Glubran 2 acrylic glue. *Cardiovasc Interv Radiol*. 2008 Sep-Oct;31(5):1030-3.
41. Gorlitz M, Mertikang G, Trnka H, Froeschl A, Meinhardt J, Weiss G, Grabenwoger M, Rand T. Translumbal treatment of type II endoleaks after endovascular repair of abdominal aortic aneurysm. *Interact Cardiovasc Thorac Surg*. 2008 Oct;7(5):781-4.
42. Keeling AN, Costello R, Lee MJ. Rasmussen's aneurysm: a forgotten entity? *Cardiovasc Interv Radiol*. 2008 Jan-Feb;31(1):196-200.
43. Heye S, Maleux G, Wilms G. Pain experience during internal spermatic vein embolization for varicocele: comparison of two cyanoacrylate glues. *Eur Radiol*. 2006 Jan;16(1):132-6.
44. Gandini R, Spinelli A, Konda D, Reale CA, Fabiano S, Pipitone V, Simonetti G. Superselective embolization in posttraumatic spinal injury with Glubran 2 acrylic glue. *Cardiovasc Interv Radiol*. 2004 Sep-Oct;27(5):544-8.
45. Schoder M, Cartes-Zumelzu F, Grabenwoger M, Cejna M, Funovics M, Krenn GC, Hutschala D, Wolf F, Thurnher S, Kretschmer G, Lammner J. Elective endovascular stent-graft repair of atherosclerotic thoracic aortic aneurysms: clinical results and midterm follow-up. *AJR Am J Roentgenol*. 2005 Mar;180(3):709-15.
46. Mauri G, Pescatori L, Mattiuz C, Poretto D, Pedicini V, Melchiorre F, Rossi U, Sobbiati L, Sconza LM. Non-healing post-surgical fistula: treatment with image-guided percutaneous injection of cyanoacrylic glue. *Radiol Med*. 2017 Feb;122(2):88-94.
47. Andronic O, Alexa D, Velicescu B. Outcome of internal Hemipelvectomy in a patient with multiple myeloma-case report. *Rev Med Chir*. 2016 Nov;120.
48. Abdumalik G, Chevallier O, Falvo N, Di Marco L, Bertalet A, Moulin B, Abi-Khalil C, Gehin S, Charles PE, Latournerie M, Midulla M, Loffroy R. Safety and efficacy of transcatheter embolization with Glubran 2 cyanoacrylate glue for acute or chronic intracranial aneurysms: a single-center experience with 104 patients. *Abdom Radiol (NY)*. 2016 Mar;41(3):723-733.
49. Gandini R, Chiochi M, Morsetti D, Chieravallotti A, Lorenz G, Simonetti G. Transcatheter endoleak embolization (TCEE) of type I and II endoleaks occurring after endovascular abdominal aortic aneurysm repair (EVAR) CIRSE 2015
50. Saiz-Mendiguren R, Samuel-Espin RS, Llopis-Lardo M. Transilic biopsy of a deep pelvic mass with ultrasonic embolization of the biopsy path. *Saiz-Mendiguren*. *Falciotomica*. 2016;16(4):30-3
51. Berthod PE, Chevallier O, Latournerie M, Gehin S, Falvo N, Midulla M, Loffroy R. Atypical use of ALN inferior vena cava filters as protection devices prior to embolization of a large portosystemic shunt with Amplatzer Vascular Plug and Glubran 2 cyanoacrylate glue. *Quant Imaging Med Surg*. 2015 May;5(4):452-456.
52. Sungmin Woo, Chang Jin Yoon, Jin Wook Chung, Sung-Gwon Kang, Hwan Jun Jae, Hyo-Chul Kim, Nak Jong Seong, Young-Joo Kim, Young-Nam Yoo, Control Hemiparesis, Comparison of N-Butyl-2-Cyanoacrylate and Polyvinyl Alcohol Particles Radiology. Volume 269, Number 2—November 2013
53. Del Corso A, Bargellini I, Coccarolo A, Perrone O, Leo M, Lunardi A, Alberti A, Tomei F, Cioni R, Ferrari M, Bartolozzi C. Efficacy and safety of a novel vascular closure device (Glubran 2 seal) after diagnostic and interventional angiography in patients with peripheral arterial occlusive disease. *Cardiovasc Interv Radiol*. 2013 Apr;36(2):371-6.
54. Emiel B J, Sturm, and Luc Defeyere. Acute Non-variceal Gastrointestinal Hemorrhage April 2010 Endoscopic Update
55. Gajewska K, Herinckx A, Holyea A, D'Haene N, Massez A, Cassart M, Van Rysselberghe M, Donner C. Antenatal embolization of a large choroidal polyp by percutaneous Glubran 2 injection. *Ultrasound Obstet Gynecol*. 2010 Dec;36(6):773-5.
56. Loffroy R, Kretz B, Guib B, Bouchot O, Cerceul JP, Brenot R, Krause D, Steinmetz E. Embolisation percutanée transabdominale d'une enduite de type 28 sur stent-graft aortique abdominal J Radiol 2010;91:90-14.
57. Loffroy R. Embolization for Upper GI Bleeding. *WVLS*. 15. 04. APRIL 2016 Endovascular Today.
58. Lee HH, Park JM, Chun JH, Oh JS, Ahn JH, Choi MS. Transcatheter arterial embolization for endoscopically unmanageable upper gastrointestinal bleeding. *Scand J Gastroenterol*. 2015 Jul;50(7):809-15. doi: 10.3109/00368225.2015.1005009. Epub 2015 May 2.
59. Cotroneo E, Gigli R, Casasco A. Fistole artero-venose midollari giganti con drenaggio venoso peridurale. Trattamento endovascular. *Rivista di Neuroradiologia* 16 (suppl. 1): 150-152 2003.
60. Nimi Y, Berenstein A, Setton A. Complications and their management during NBCA embolization of craniospinal Lesions. *Interventional Neuroradiology* 9 (Suppl1): 157-164, 2003.
61. Levrier O, Mekkaoui C, Rolland PH, Murphy K, Cabrol P, Moulin G, Bartoli JM, Raybaud C. Efficacy and low vascular toxicity of embolization with radical versus anionic polymerization of n-butyl-2-cyanoacrylate (NBCA). An experimental study in the swine. *J Neuroradiol*. 2003 Mar;30(3):395-102.
62. Roberto De Biasi. Glubran 2 nel trattamento di MAV cerebrali non-adergenti ed emorragiche. *Edizione GEM* 2016.
63. Leonard M., Barbara C., Simonetti L., Giardino R., Cioni R., Almagiari N., Fini M., Martini L., Masetti L., Joehler M., Roncaroli F. Glubran 2: A New Acrylic Glue for Neuroendovascular Endovascular Use. *Experimental Study on Animals*. *Interventional Neuroradiology* 8: 245-250, 2002
64. Leonard M., Cenni P., Simonetti L., Bozzano A., Romano A., Bonamini M., Fantozzi LM, Fini G. Glubran 2 (r): a new acrylic glue for neuroendovascular endovascular use: a complementary histological study. *Interv Neuroradiol*. 2003 Sep 30;9(3):249-54. Epub 2004 May 12.
65. Perini S., Castellani L., Casini F. Malformazioni artero-venose cerebrali: neurodiagnostica terapeutica. *Neurol. Sci.* (2002) 23: S273-S275
66. Cotroneo E., Gigli R., Casasco A. L'embolizzazione per via arteriosa e venosa delle fistole artero-venose intracraniche. *Rivista di Neuroradiologia* 2003, 16 (suppl. 1): 38-42
67. Rafi L., Simonetti L., Cenni P., Bandieri S., Gasbarri A., Borlani S., Leonard M. Presurgical embolization of spinal tumours using Glubran 2 acrylic glue. *Interv Neuroradiol*. 2003 Dec;20(9):4339-49. Epub 2004 Oct 22.
68. Abud DG, Mouyener C, Benndorf G, Plotin M, Spelle L, Morel L. Intracranial injection of cyanoacrylate glue in head and neck paranasal sinuses. *AJNR Am J Neuroradiol*. 2004 Oct;25(9):1457-62. L.
69. Simonetti L., Rafi P., Cenni A., Andreoli F., Calducci M., Leonard M. Presurgical embolization of intracranial extra-axial tumors using Glubran 2: our experience in 14 patients. *Rivista di Neuroradiologia* 2004; 17: 645-658
70. Barbara C., Pozzati E., Maruccci G., Joehler M., Pisoni L., Bellei E., Leonard M., Masetti L. Effects of Glubran 2 acrylic glue on the subarachnoid space in swine peripheral findings. *Rivista di Neuroradiologia* 2005; 18: 537-545.
71. Desai HA, Toulgout F, Raoult S, Guillou B, Al Hammal Ibrahim R, Aufray-Calvier E, De Kersant-Gilly A. Brain arteriovenous malformations technical note of endovascular treatment with Glubran. *Interv Neuroradiol*. 2005 Oct 1;11(Suppl 1):132-30.
72. Rafi L., Simonetti L., Cenni P., Leonard M. Use of Glubran 2 acrylic glue in interventional neuroradiology. *Neuroradiology* (2007) 49:829-838
73. Chapiro R., Saint-Maurice JP, Narata AP, Rogopoulou A, Moreau JH, Houdart E, Maubon A. Transcranial puncture through the parietal and mastoid foramina for the treatment of dural fistulas. Report of four cases. *J Neurosurg*. 2007 May;106(5):912-5.
74. J. Kirsch, C. Eger, V. Sychara, C. Strassla, S. Basche, J. Weber. Stent-Assisted Coil Embolization of Posterior Circulation Aneurysms Using Software Abi. *Preliminary Experience*: August 2009 - Volume 65 - Issue 2 - p 258-266
75. Wang Y, Zhang H, Ling F. Coexistence of a single cerebral arteriovenous malformation and spinal arteriovenous malformation. *Neuro Endocrinol*. 2009Nov-Dec;57(6):785-8.
76. Rosetti S. Spontaneous Intracerebral and Intraventricular Hemorrhage. *Clin Neuroimaging* (2010); 20: 131-134.
77. Gaudin P., Gallardi S., Boulain A., Conditte-Auloux S., Bourdin F., Guleu S., Dupuy M., Rodesgh G. Therapeutic management of intracranial aneurysms shunts with leptomeningeal fistulas: report of 85 consecutive patients with emphasis on transarterial embolization with acrylic glue. *J Neurosurg*. 2010; 112: 603-610.
78. Abdel Kerim A, Bonnevillie F, Jean B, Cornu P, LeJean L, Chiras J, Balloun-assisted embolization of skull base meningiomas with liquid embolic agent. *J Neurosurg*. 2010 Jan;112(1):70-2.
79. Zheng-Ran Li, Zai-Bo Jiang, Ming-Sheng Huang, Kang-Shun Zhu, Qing Wang, Hong Shan. Transvenous embolization of cavernous sinus dural arteriovenous fistulas using detachable coils and Glubran 2 acrylic glue via the inferior petrosal sinus approach. *Eur Radiol* (2010) 20: 2399-2947
80. Luo Q, Luo H, Wang K, Xu J, Yu. Endovascular Treatments for Distal Posterior Cerebral Artery Aneurysms. *Turkish Neurosurgery* 2012; Vol. 22, 141-147.
81. Liu J, Lv M, Lv X, He H, Li A, Qian Z, Li Y. Curative Glubran 2 Embolization of cerebral arteriovenous malformations: patient selection and initial results. *Interv Neuroradiol*. 2014 Dec;20(6):722-8.
82. Li Y, Barthes-Biesel D, Salas AV. Polymerization kinetics of n-butyl cyanoacrylate glues used for vascular embolization. *J Mech Behav Biomed Mater*. 2017 May;69:307-317.
83. Pictures kindly provided by Poretto D., Pedicini V., Lanza E. Interventional Radiology Center of the Clinical Institute Humanitas-Rozzano (MI) -Italy
84. Modified by the label "Lipiodol and cyanoacrylate-based glue (Glubran2/NBCA) mixing process". July 2019 Ed. Gurbet

